In addition, participants on once-weekly insulin icodec had a higher time in range (70-180 mg/dL) than participants on either once-daily insulin glargine U100 or Tresiba. The severe/clinically significant hypoglycemia rates were also lower with once-weekly insulin icodec than with the once-daily comparators.
These results suggest that once-weekly insulin icodec is a safe and effective treatment option for insulin-naïve adults with T2D. It provides superior glycemic control with a lower risk of hypoglycemia than once-daily insulin glargine and Tresiba.
Insulin icodec is currently under regulatory review in multiple countries and is expected to be available in the first half of 2024.
